First participant treated at the highest dose level in Clarity’s theranostic prostate cancer trial

Sydney, Australia 25 August 2023

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the dosing of the first participant at the highest dose level of 12GBq in the third cohort of its Phase I/II theranostic trial evaluating ⁶⁷Cu SAR-bisPSMA in participants with metastatic, castrate-resistant prostate cancer (mCRPC).

The SECuRE trial (NCT04868604)¹ is a Phase I/IIa theranostic trial for identification and treatment of participants with Prostate-Specific Membrane Antigen (PSMA)-expressing mCRPC using ⁶⁴Cu/⁶⁷Cu SAR-bisPSMA. ⁶⁴Cu SAR-bisPSMA is used to visualise PSMA-expressing lesions and select candidates for subsequent ⁶⁷Cu SAR-bisPSMA therapy. The trial is a multi-centre, single arm, dose escalation trial with a cohort expansion involving up to 44 participants in the US. The overall aim of the trial is to determine the safety and efficacy of ⁶⁷Cu SAR-bisPSMA for the treatment of prostate cancer.

Cohort 3 explores the effects of the highest dose of 12GBq on the SECuRE trial participants following a single administration of ⁶⁷Cu SAR-bisPSMA. The third cohort will be the last to assess single doses of ⁶⁷Cu SAR-bisPSMA and will be followed by a multi-dose cohort, pending safety evaluation.

The first two cohorts in the dose escalation phase of the trial were successfully completed with no DLTs reported in any of the participants dosed. The 3 participants in cohort 2, who were administered a single dose of 8GBq of ⁶⁷Cu SAR-bisPSMA, have been monitored by their physicians for safety and treatment response as per the trial protocol. All 3 participants in cohort 2 remain on the trial following their administration of 8GBq of ⁶⁷Cu SAR-bisPSMA, with all 3 participants exhibiting a greater than 50% reduction in PSA, which is one of the primary endpoints of the SECuRE trial and a commonly used surrogate endpoint for efficacy in this patient population. PSA levels continue to fall in all patients, with the first 2 participants showing reductions of greater than 95% and the last participant showing a drop of approximately 70% so far.

⁶⁴Cu SAR-bisPSMA PET/CT imaging before and after a single cycle of 8GBq ⁶⁷Cu SAR-bisPSMA (cohort 2)

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “Results from cohort 2 are incredibly exciting and we look forward to seeing data from the increased dosing of 12GBq as well as discover the potential positive effects of multi-dosing on prostate cancer patients.

“The fast pace of recruitment into the dose escalation phase of the trial is indicative of the high unmet need in the prostate cancer therapy space and we are thrilled to be working on a solution that has potential to not only offer treatment benefits to patients with mCRPC, but also resolve the logistical and manufacturing challenges of the current-generation radiopharmaceuticals, such as ¹⁷⁷Lu PSMA-617, especially now with the availability of commercial quantities of the ⁶⁷Cu radioisotope routinely produced domestically in the US and exclusively supplied to us by NorthStar.

“We look forward to sharing more data on ⁶⁷Cu SAR-bisPSMA as we continue to recruit participants into the SECuRE trial and progress on our path towards commercialisation with the ultimate goal of improving treatment outcomes for people with cancer,” said Dr Taylor.

Overview of Clarity’s SAR-bisPSMA clinical program

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word “bis”, which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a TCT that can be used with isotopes of copper-64 (Cu-64 or ⁶⁴Cu) for imaging and copper-67 (Cu-67 or ⁶⁷Cu) for therapy. For more information, see: http://y2u.be/QJz7dyxdEJo. ­

⁶⁴Cu SAR-bisPSMA and ⁶⁷Cu SAR-bisPSMA are unregistered products. Individual results may not represent the overall safety and efficacy of the products. The data outlined in this announcement has not been assessed by health authorities such as the US Food and Drug Administration (FDA). A clinical development program is currently underway to assess the efficacy and safety of these products. There is no guarantee that these products will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death worldwide². The American Cancer Institute estimates in 2023 there will be 288,300 new cases of prostate cancer in the US and around 34,700 deaths from the disease³.

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing TCTs based on its SAR technology platform for the treatment of children and adults with cancer.

www.claritypharmaceuticals.com

References

1. ClinicalTrials.gov Identifier: NCT04868604, https://clinicaltrials.gov/ct2/show/NCT04868604
2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660
3. American Cancer Society: Key Statistics for Prostate Cancer, https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html

Media Contacts

Clarity Pharmaceuticals

Dr Alan Taylor
Executive Chairman
+61 (0)413 871 165
ataylor@claritypharm.com

Citadel-MAGNUS

Catherine Strong
Investor/Media Relations
+61 (0)406 759 268
cstrong@citadelmagnus.com

This announcement has been authorised for release by the Executive Chairman.